NCT00785850

CompletedPhase 3

Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety.

Sanofi Source

Compare

Other study identifiers

Sponsor study identifier

LACAC_L_04301

Study Type

interventional

Actual enrollment (reported)

31

Locations

1 country

Sites

1

Timeline

Study Start

August 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

September 2008

Actual (reported)

Study Completion

Not reported

Date not reported

Brief Summary

To prove the safety in normal conditions of use.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 31 participants
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 2008
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
September 2008
Actual (reported)
First Submitted
November 4, 2008
Actual (reported)
First Posted
November 5, 2008
Actual (reported)

Last Updated: March 6, 2009
Status Verified: March 2009
Last Update Submitted: March 5, 2009

Conditions

Hygiene

Outcome Measures

Primary Outcomes (1)

The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.
From the treatment start to the end of the study

Study Arms (1)

1

EXPERIMENTAL

Dermacyd PH\_DETINBACK (Lactic Acid) Sweet Flower

Drug: Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower

Interventions

Dermacyd PH_DETINBACK (Lactic Acid) Sweet FlowerDrug

1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age10 Years - 20 Years

Sexfemale

Healthy VolunteersYes

Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

Integral skin test in the region;
Use of cosmetic product of the same category;

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (1)

Sanofi-Aventis Administrative Office

São Paulo, Brazil

MeSH Terms

Interventions

Lactic Acid

Intervention Hierarchy (Ancestors)

LactatesHydroxy AcidsCarboxylic AcidsOrganic Chemicals

Study Officials

Jaderson Lima
Sanofi
STUDY DIRECTOR

Enrollment

31 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: SUPPORTIVE CARE
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

November 4, 2008

First Posted

November 5, 2008

Study Start

August 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00785590

Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.

Phase 3Completed

NCT00785655

Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Compatibility

Phase 3Completed

NCT00783666

Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation

Phase 3Completed

NCT00785642

Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.

Phase 3Completed

NCT00663273

Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower

Phase 3Completed

NCT00663325

Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower

Phase 3Completed

Willingness in following the study procedures and to be present in the clinic at the days and scheduled time;

You may not qualify if:

Lactation or gestational risk or gestation;
Use of Anti-inflammatory, immunosuppression or anti-histaminic drugs;
Atopic antecedent or allergic to cosmetic product;
Active cutaneous disease in the evaluation area;
Diseases which cause immunology decrease, such as diabetes and HIV;
Endocrinal pathologies;
Intense solar exposure 15 days before the evaluation;
Treatment until four months before the selection
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contact the study team to confirm eligibility.

Primary Completion

September 2008

Actual (reported)

Last Updated

March 6, 2009

Record last verified: 2009-03

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00785850
Data provider: ClinicalTrials.gov
Source updated: 2009-03-06
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:30:29 UTC

Locations

BR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations